Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06004960 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants

A Phase 1 study, sponsored by Amgen.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target

NCT06004960 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 6 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06004960, a Phase 1 study, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target

Study Summary

The primary objective of this study is to perform mass balance following a single oral dose of \[14C\]CCX168 in healthy adult male participants.

Interventions

  • DRUG [14C]CCX168

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2014-10-20
Est. Completion 2014-12-05
Phase Phase 1

Sponsor

Amgen

558 total trials

What the Registry Record Tells You About NCT06004960

The ClinicalTrials.gov registry entry for NCT06004960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which [14C]CCX168 is the first listed.

NCT06004960 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06004960 about?

NCT06004960 is a clinical study titled "A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants". The primary objective of this study is to perform mass balance following a single oral dose of \[14C\]CCX168 in healthy adult male participants.

What is the current status of trial NCT06004960?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-10-20. Estimated completion is 2014-12-05.

What interventions are being tested in trial NCT06004960?

The interventions under investigation include: [14C]CCX168 (DRUG).

Who is sponsoring clinical trial NCT06004960?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.